

Patrizia Burra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6602382/publications.pdf>

Version: 2024-02-01

467
papers

18,054
citations

14655

66
h-index

20961

115
g-index

479
all docs

479
docs citations

479
times ranked

14604
citing authors

#	ARTICLE	IF	CITATIONS
1	The application of artificial intelligence in hepatology: A systematic review. <i>Digestive and Liver Disease</i> , 2022, 54, 299-308.	0.9	13
2	An Essential Guide for Managing Post-Liver Transplant Patients: What Primary Care Physicians Should Know. <i>American Journal of Medicine</i> , 2022, 135, 157-166.	1.5	4
3	Ethical review of COVID-19 vaccination requirements for transplant center staff and patients. <i>American Journal of Transplantation</i> , 2022, 22, 371-380.	4.7	35
4	A prospective longitudinal assessment of <i>de novo</i> metabolic syndrome after liver transplantation. <i>Clinical Transplantation</i> , 2022, 36, e14532.	1.6	7
5	State of the art treatment of hepatitis B virus hepatocellular carcinoma and the role of hepatitis B surface antigen post-liver transplantation and resection. <i>Liver International</i> , 2022, 42, 288-298.	3.9	5
6	The EASL "Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. <i>Lancet</i> , The, 2022, 399, 61-116.	13.7	257
7	Liver transplantation for severe alcoholic hepatitis: A multicenter Italian study. <i>American Journal of Transplantation</i> , 2022, 22, 1191-1200.	4.7	29
8	Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 500.	4.1	37
9	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 1-16.	2.6	15
10	Letter to the editor: Is PAI a thrombotic biomarker in NASH cirrhosis?. <i>Hepatology</i> , 2022, 76, E16-E17.	7.3	1
11	R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation. <i>JHEP Reports</i> , 2022, 4, 100445.	4.9	6
12	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). <i>Digestive and Liver Disease</i> , 2022, 54, 170-182.	0.9	12
13	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. <i>Journal of Hepatology</i> , 2022, 77, 84-97.	3.7	21
14	Haemostatic alterations in patients with cirrhosis and hepatocellular carcinoma: laboratory evidence and clinical implications. <i>Liver International</i> , 2022, 42, 1229-1240.	3.9	17
15	Nash Up, Virus Down: How the Waiting List Is Changing for Liver Transplantation: A Single Center Experience from Italy. <i>Medicina (Lithuania)</i> , 2022, 58, 290.	2.0	6
16	The role of preoperative optimization of the nutritional status on the improvement of short-term outcomes after liver transplantation? A review of the literature and expert panel recommendations. <i>Clinical Transplantation</i> , 2022, 36, e14647.	1.6	10
17	COVID-19 and liver disease: where are we now?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 277-278.	17.8	19
18	Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death. <i>Journal of Hepatology</i> , 2022, 77, 660-669.	3.7	43

#	ARTICLE	IF	CITATIONS
19	HBV-positive and HIV-positive organs in transplantation: a clinical guide for the hepatologist. <i>Journal of Hepatology</i> , 2022, , .	3.7	4
20	Global hemostatic profiling in patients with decompensated cirrhosis and bacterial infections. <i>JHEP Reports</i> , 2022, 4, 100493.	4.9	17
21	Digestive cancer screening across Europe. <i>United European Gastroenterology Journal</i> , 2022, 10, 435-437.	3.8	8
22	Transplanting severely obese cirrhotic patients: Heavy clouds still on the horizon. <i>United European Gastroenterology Journal</i> , 2022, 10, 445-446.	3.8	0
23	Evaluation of the Kinetics of Antibody Response to COVID-19 Vaccine in Solid Organ Transplant Recipients: The Prospective Multicenter ORCHESTRA Cohort. <i>Microorganisms</i> , 2022, 10, 1021.	3.6	13
24	Sex bias in clinical trials in gastroenterology and hepatology. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 413-414.	17.8	12
25	Staging the pre-procedural prophylaxis in decompensated cirrhosis. <i>Digestive and Liver Disease</i> , 2022, 54, 1130-1132.	0.9	5
26	Gender and Autoimmune Liver Diseases: Relevant Aspects in Clinical Practice. <i>Journal of Personalized Medicine</i> , 2022, 12, 925.	2.5	10
27	Reply to "Peripheral versus central venous blood sampling does not influence the assessment of platelet activation in cirrhosis". <i>Platelets</i> , 2022, 33, 1104-1106.	2.3	6
28	<scp>Sarsâ€Cov</scp>â€2 vaccination in liver transplant recipients: The "holy grail"â€™ in a hostile environment. <i>Liver International</i> , 2022, 42, 1225-1228.	3.9	4
29	A Commentary on the Interplay Between Severity of Liver Disease and Bacterial Infection in Hospitalized Patients with Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2021, 66, 640-641.	2.3	1
30	Response to Terlipressin and Albumin Is Associated With Improved Liver Transplant Outcomes in Patients With Hepatorenal Syndrome. <i>Hepatology</i> , 2021, 73, 1909-1919.	7.3	53
31	Therapeutic approaches for the treatment of aging-induced stem cell dysfunction. , 2021, , 223-230.		0
32	Solid Organ Transplantation During COVID-19 Pandemic: An International Web-based Survey on Resourcesâ€™ Allocation. <i>Transplantation Direct</i> , 2021, 7, e669.	1.6	3
33	A challenging liver transplantation for decompensated alcoholic liver disease after recovery from SARSâ€Covâ€2 infection. <i>Transplant International</i> , 2021, 34, 756-757.	1.6	6
34	Hepatocellular carcinoma and the risk of de novo malignancies after liver transplantation " a multicenter cohort study. <i>Transplant International</i> , 2021, 34, 743-753.	1.6	5
35	Machine learning in liver transplantation: a tool for some unsolved questions?. <i>Transplant International</i> , 2021, 34, 398-411.	1.6	21
36	Malnourished cirrhotic patient: what should we do?. <i>Minerva Gastroenterology</i> , 2021, 67, 11-22.	0.5	3

#	ARTICLE	IF	CITATIONS
37	Hepatocellular carcinoma risk in patients with HBV-related liver disease receiving antiviral therapy. <i>Minerva Gastroenterology</i> , 2021, 67, .	0.5	7
38	Drug induced liver injury: from pathogenesis to liver transplantation. <i>Minerva Gastroenterology</i> , 2021, 67, .	0.5	7
39	Management of complex liver diseases. <i>Minerva Gastroenterology</i> , 2021, 67, 2-3.	0.5	2
40	Severe acute alcoholic hepatitis: can we offer early liver transplantation?. <i>Minerva Gastroenterology</i> , 2021, 67, .	0.5	4
41	Influence of Hepatocellular Carcinoma on Platelet Aggregation in Cirrhosis. <i>Cancers</i> , 2021, 13, 1150.	3.7	21
42	Current and future perspective on targeted agents and immunotherapies in hepatocellular carcinoma. <i>Minerva Gastroenterology</i> , 2021, 67, .	0.5	7
43	The Need for Consensus About Liver Transplantation For Patients With Neuropsychiatric Wilson's Disease. <i>Progress in Transplantation</i> , 2021, 31, 168-170.	0.7	1
44	Management of portal hypertension severe complications. <i>Minerva Gastroenterology</i> , 2021, 67, .	0.5	3
45	Liver Transplantation for T2 Hepatocellular Carcinoma during the COVID-19 Pandemic: A Novel Model Balancing Individual Benefit against Healthcare Resources. <i>Cancers</i> , 2021, 13, 1416.	3.7	8
46	Sustained Complete Response after Biological Downstaging in Patients with Hepatocellular Carcinoma: XXL-Like Prioritization for Liver Transplantation or "Wait and See" Strategy?. <i>Cancers</i> , 2021, 13, 2406.	3.7	7
47	Determinants of increased thrombotic tendency in NASH cirrhosis: not there yet!. <i>Transplant International</i> , 2021, 34, 1325-1327.	1.6	1
48	Breakthrough invasive fungal infection after liver transplantation in patients on targeted antifungal prophylaxis: A prospective multicentre study. <i>Transplant Infectious Disease</i> , 2021, 23, e13608.	1.7	11
49	Italian association for the study of the liver position statement on SARS-CoV2 vaccination. <i>Digestive and Liver Disease</i> , 2021, 53, 677-681.	0.9	13
50	Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). <i>Liver International</i> , 2021, 41, 1713-1733.	3.9	58
51	Position paper on liver and kidney diseases from the Italian Association for the Study of Liver (AISF), in collaboration with the Italian Society of Nephrology (SIN). <i>Digestive and Liver Disease</i> , 2021, 53, S49-S86.	0.9	7
52	International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria. <i>JHEP Reports</i> , 2021, 3, 100331.	4.9	10
53	Presepsin as a biomarker of inflammation and prognosis in decompensated liver disease. <i>Journal of Hepatology</i> , 2021, 75, 232-234.	3.7	4
54	Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. <i>Liver International</i> , 2021, 41, 2455-2466.	3.9	29

#	ARTICLE	IF	CITATIONS
55	The Current Management of Hepatorenal Syndromeâ€“Acute Kidney Injury in the United States and the Potential of Terlipressin. <i>Liver Transplantation</i> , 2021, 27, 1191-1202.	2.4	23
56	Limitations of current liver donor allocation systems and the impact of newer indications for liver transplantation. <i>Journal of Hepatology</i> , 2021, 75, S178-S190.	3.7	30
57	More Pronounced Hypercoagulable State and Hypofibrinolysis in Patients With Cirrhosis With Versus Without HCC. <i>Hepatology Communications</i> , 2021, 5, 1987-2000.	4.3	16
58	New Indications for Liver Transplantation. <i>Journal of Clinical Medicine</i> , 2021, 10, 3867.	2.4	20
59	Recent Advances in the Management of Acute Variceal Hemorrhage. <i>Journal of Clinical Medicine</i> , 2021, 10, 3818.	2.4	12
60	Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation. <i>Cancers</i> , 2021, 13, 4882.	3.7	15
61	Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: Results of the ELITA/EF-CLIF collaborative study (ECLIS). <i>Journal of Hepatology</i> , 2021, 75, 610-622.	3.7	96
62	Coronary artery calcium on standard chest computed tomography predicts cardiovascular events after liver transplantation. <i>International Journal of Cardiology</i> , 2021, 339, 219-224.	1.7	8
63	Safe pregnancy after liver transplantation: Evidence from a multicenter Italian collaborative study. <i>Digestive and Liver Disease</i> , 2021, , .	0.9	0
64	Clinical update on the efficacy of anti-SARS-CoV-2 mRNA vaccines in patients on the waiting list for liver transplantation and in liver transplant recipients. <i>Digestive and Liver Disease</i> , 2021, 53, 1232-1234.	0.9	8
65	Comparison of Fondaparinux and Low-Molecular-Weight Heparin in the Treatment of Portal Vein Thrombosis in Cirrhosis. <i>American Journal of Medicine</i> , 2021, 134, 1278-1285.e2.	1.5	15
66	Development of a Risk Prediction Model for Carbapenem-resistant<i>Enterobacteriaceae</i> Infection After Liver Transplantation: A Multinational Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e955-e966.	5.8	22
67	Diagnostic and prognostic role of presepsin in patients with cirrhosis and bacterial infection. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 775-782.	2.3	12
68	Severe acute alcoholic hepatitis: can we offer early liver transplantation?. <i>Minerva Gastroenterology</i> , 2021, 67, 23-25.	0.5	4
69	Management of portal hypertension severe complications. <i>Minerva Gastroenterology</i> , 2021, 67, 26-37.	0.5	3
70	COVIDâ€“19 and digestive health: Implications for prevention, care and the use of COVIDâ€“19 vaccines in vulnerable patients. <i>United European Gastroenterology Journal</i> , 2021, 9, 1091-1095.	3.8	8
71	Toward a novel evidenceâ€“based definition of early allograft failure in the perspective of liver retransplant. <i>Transplant International</i> , 2021, 34, 2905-2907.	1.6	1
72	Current and future perspective on targeted agents and immunotherapies in hepatocellular carcinoma. <i>Minerva Gastroenterology</i> , 2021, 67, 4-10.	0.5	3

#	ARTICLE	IF	CITATIONS
73	Antibiotic therapy for spontaneous bacterial peritonitis in acute-on-chronic liver failure: Handle with care. <i>Digestive and Liver Disease</i> , 2020, 52, 116-117.	0.9	1
74	Changes in plasma circulating microvesicles in patients with HCV-related cirrhosis after treatment with direct-acting antivirals. <i>Liver International</i> , 2020, 40, 913-920.	3.9	12
75	Including Relative Adrenal Insufficiency in Definition and Classification of Acute-on-Chronic Liver Failure. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1188-1196.e3.	4.4	39
76	Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance. <i>Journal of Viral Hepatitis</i> , 2020, 27, 188-194.	2.0	20
77	Outcomes of Liver Transplant for Adults With Wilson's Disease. <i>Liver Transplantation</i> , 2020, 26, 507-516.	2.4	12
78	Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting. <i>Gut</i> , 2020, 69, 764-780.	12.1	112
79	mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors. <i>Annals of Surgery</i> , 2020, 272, 855-862.	4.2	85
80	De novo and recurrent malignancy. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2020, 46-47, 101680.	2.4	10
81	From the Editor's Desk . <i>Journal of Hepatology</i> , 2020, 73, 1001-1004.	3.7	0
82	Endothelial Damage of the Portal Vein is Associated with Heparin-Like Effect in Advanced Stages of Cirrhosis. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1173-1181.	3.4	41
83	From the Editor's Desk . <i>Journal of Hepatology</i> , 2020, 73, 475-478.	3.7	0
84	NAFLD and liver transplantation: Disease burden, current management and future challenges. <i>JHEP Reports</i> , 2020, 2, 100192.	4.9	96
85	From the Editor's Desk.... <i>Journal of Hepatology</i> , 2020, 73, 745-748.	3.7	0
86	Reassessment of the risk of recurrence (R3) after liver transplantation for HCC: validation of the R3 v.2 score and comparison with existing models: results of a multinational analysis in 2,444 patients. <i>Journal of Hepatology</i> , 2020, 73, S9-S11.	3.7	0
87	De novo metabolic syndrome after liver transplantation: a prospective, longitudinal study. <i>Journal of Hepatology</i> , 2020, 73, S253-S254.	3.7	0
88	Long-term liver fibrosis and outcomes in HCV-infected solid organ transplant recipients after DASSs-induced viral eradication. <i>Journal of Hepatology</i> , 2020, 73, S609-S610.	3.7	0
89	Bidimensional shear wave elastography of the rectus femoris muscle in patients with cirrhosis. <i>Journal of Hepatology</i> , 2020, 73, S696.	3.7	1
90	Development and Validation of a Comprehensive Model to Estimate Early Allograft Failure Among Patients Requiring Early Liver Re transplant. <i>JAMA Surgery</i> , 2020, 155, e204095.	4.3	67

#	ARTICLE	IF	CITATIONS
91	Influence of donor and recipient gender on liver transplantation outcomes in Europe. <i>Liver International</i> , 2020, 40, 1961-1971.	3.9	22
92	From the Editor's Desk. <i>Journal of Hepatology</i> , 2020, 72, 1039-1042.	3.7	0
93	Cholangiocarcinoma as an Indication for Liver Transplantation in the Era of Transplant Oncology. <i>Journal of Clinical Medicine</i> , 2020, 9, 1353.	2.4	10
94	Clinical implications of COVID-19 in patients with chronic liver disease and liver tumor. <i>Updates in Surgery</i> , 2020, 72, 237-239.	2.0	6
95	Biodegradable Biliary Stents for Percutaneous Treatment of Post-liver Transplantation Refractory Benign Biliary Anastomotic Strictures. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 749-755.	2.0	14
96	From the Editor's Desk. <i>Journal of Hepatology</i> , 2020, 73, 227-230.	3.7	0
97	Ductular reaction and hepatocyte ballooning identify patients with fibrosing cholestatic hepatitis after liver transplantation. <i>Gastroenterology & Hepatology (English Edition)</i> , 2020, 43, 14-21.	0.1	0
98	Ductular reaction and hepatocyte ballooning identify patients with fibrosing cholestatic hepatitis after liver transplantation. <i>Gastroenterology & Hepatology</i> , 2020, 43, 14-21.	0.5	2
99	Switch from intravenous or intramuscular to subcutaneous hepatitis B immunoglobulin: effect on quality of life after liver transplantation. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 99.	2.4	3
100	HCC recurrence in HCV-infected patients after liver transplantation: SiLVER Study reveals benefits of sirolimus in combination with CNIs: a post-hoc analysis. <i>Transplant International</i> , 2020, 33, 917-924.	1.6	4
101	Posttransplant Management of Recipients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Working Group Report From the ILTS Transplant Oncology Consensus Conference. <i>Transplantation</i> , 2020, 104, 1143-1149.	1.0	41
102	Invasive fungal infection before and after liver transplantation. <i>World Journal of Gastroenterology</i> , 2020, 26, 7485-7496.	3.3	26
103	<i>Geotrichum capitatum</i> Invasive Infection Early After Liver Transplant. <i>Experimental and Clinical Transplantation</i> , 2020, 18, 737-740.	0.5	2
104	Survival after the diagnosis of <i>de novo</i> malignancy in liver transplant recipients. <i>International Journal of Cancer</i> , 2019, 144, 232-239.	5.1	28
105	Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics. <i>Cancers</i> , 2019, 11, 1568.	3.7	27
106	FRI-403-Impact on post liver transplant outcomes of response to treatment with terlipressin and albumin in patients with hepatorenal syndrome. <i>Journal of Hepatology</i> , 2019, 70, e572.	3.7	0
107	Physical Condition, Glycemia, Liver Function, and Quality of Life in Liver Transplant Recipients After a 12-Month Supervised Exercise Program. <i>Transplantation Proceedings</i> , 2019, 51, 2952-2957.	0.6	13
108	THU-071-Matrix modulation in chronic liver injury and resolution. <i>Journal of Hepatology</i> , 2019, 70, e190.	3.7	0

#	ARTICLE	IF	CITATIONS
109	SAT-034-The psychomotor vigilance task: Role in the diagnosis of hepatic encephalopathy and relationship with driving ability. <i>Journal of Hepatology</i> , 2019, 70, e641.	3.7	0
110	P.04.7 PREVALENCE OF DE NOVO METABOLIC SYNDROME AND ITS RISK FACTORS IN A LIVER TRANSPLANTED POPULATION: A PROSPECTIVE STUDY. <i>Digestive and Liver Disease</i> , 2019, 51, e174.	0.9	1
111	The psychomotor vigilance task: Role in the diagnosis of hepatic encephalopathy and relationship with driving ability. <i>Journal of Hepatology</i> , 2019, 70, 648-657.	3.7	13
112	Predictive value of induced hyperammonaemia and neuropsychiatric profiling in relation to the occurrence of post-TIPS hepatic encephalopathy. <i>Metabolic Brain Disease</i> , 2019, 34, 1803-1812.	2.9	8
113	New Perspectives in Liver Transplantation: From Regeneration to Bioengineering. <i>Bioengineering</i> , 2019, 6, 81.	3.5	19
114	SAT-115-Fondaparinux vs low molecular weight heparin in the treatment of non malignant portal vein thrombosis in patients with cirrhosis. <i>Journal of Hepatology</i> , 2019, 70, e681.	3.7	1
115	Management of Recurrent and De Novo NAFLD/NASH After Liver Transplantation. <i>Transplantation</i> , 2019, 103, 57-67.	1.0	64
116	A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 34-42.	1.6	58
117	Outcome of critically ill cirrhotic patients admitted to the ICU: The role of ACLF. <i>Journal of Hepatology</i> , 2019, 70, 801-803.	3.7	6
118	Allocation of liver grafts worldwide “ Is there a best system?. <i>Journal of Hepatology</i> , 2019, 71, 707-718.	3.7	71
119	The role of delta creatinine and serum albumin in predicting mortality in patients with severe alcoholic hepatitis and infection. <i>Digestive and Liver Disease</i> , 2019, 51, e29.	0.9	0
120	The role of alcoholic liver disease as risk factor for the development of de novo metabolic syndrome after liver transplantation: a prospective longitudinal study. <i>Digestive and Liver Disease</i> , 2019, 51, e51.	0.9	0
121	Outcome of a First Episode of Bacterial Infection in Candidates for Liver Transplantation. <i>Liver Transplantation</i> , 2019, 25, 1187-1197.	2.4	5
122	Development of a model based on case-mix analysis to predict 6-month patient survival after liver transplantation: a multicenter Italian study. <i>Digestive and Liver Disease</i> , 2019, 51, e11-e12.	0.9	0
123	De novo neoplasms after liver transplantation: donor gender and age influence. <i>Digestive and Liver Disease</i> , 2019, 51, e50.	0.9	0
124	Fondaparinux vs low molecular weight heparin in the treatment of non malignant portal vein thrombosis in patients cirrhosis. <i>Digestive and Liver Disease</i> , 2019, 51, e42.	0.9	2
125	Long-term liver function changes and related risk factors after direct-acting antiviral therapy in HCV-infected cirrhotic patients: results from a prospective web-based regional platform. <i>Digestive and Liver Disease</i> , 2019, 51, e16.	0.9	0
126	Health-related Quality of Life in Liver Transplantation: Another Step Forward. <i>Transplant International</i> , 2019, 32, 792-793.	1.6	4

#	ARTICLE	IF	CITATIONS
127	Nonalcoholic steatohepatitis before and after liver transplant: keeping up with the times. Expert Review of Gastroenterology and Hepatology, 2019, 13, 173-178.	3.0	12
128	Outcome of critically ill patients with cirrhosis and ACLF after ICU admission. Digestive and Liver Disease, 2019, 51, e14.	0.9	0
129	The ILTS Consensus Conference on NAFLD/NASH and Liver Transplantation: Setting the Stage. Transplantation, 2019, 103, 19-21.	1.0	11
130	Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Digestive and Liver Disease, 2019, 51, 190-205.	0.9	77
131	Extended Infusion of β -Lactams for Bloodstream Infection in Patients With Liver Cirrhosis: An Observational Multicenter Study. Clinical Infectious Diseases, 2019, 69, 1731-1739.	5.8	29
132	AISF position paper on HCV in immunocompromised patients. Digestive and Liver Disease, 2019, 51, 10-23.	0.9	5
133	Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis. Liver International, 2019, 39, 826-834.	3.9	15
134	International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. Transplantation, 2018, 102, 727-743.	1.0	178
135	Specific issues concerning the management of patients on the waiting list and after liver transplantation. Liver International, 2018, 38, 1338-1362.	3.9	19
136	Long-term care of transplant recipients. Current Opinion in Organ Transplantation, 2018, 23, 187-195.	1.6	29
137	Risk of virus and non-virus related malignancies following immunosuppression in a cohort of liver transplant recipients. Italy, 1985-2014. International Journal of Cancer, 2018, 143, 1588-1594.	5.1	21
138	Gender dimorphism in fibrosis dynamics in a murine model of chronic hepatic injury. Digestive and Liver Disease, 2018, 50, 4-5.	0.9	0
139	The Health Care Transition of Youth With Liver Disease Into the Adult Health System. Journal of Pediatric Gastroenterology and Nutrition, 2018, 66, 976-990.	1.8	35
140	Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study. Journal of Hepatology, 2018, 69, 345-352.	3.7	128
141	The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation: A national real-life experience. Liver International, 2018, 38, 733-741.	3.9	5
142	Sex-dependent differences in inflammatory responses during liver regeneration in a murine model of acute liver injury. Clinical Science, 2018, 132, 255-272.	4.3	21
143	Short-term outcomes of paediatric liver transplant recipients after transition to Adult Healthcare Service. Liver International, 2018, 38, 1316-1321.	3.9	9
144	A prospective multicentre study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients. Clinical Microbiology and Infection, 2018, 24, e1546-e1548.	6.0	67

#	ARTICLE	IF	CITATIONS
145	Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma. <i>Cancers</i> , 2018, 10, 450.	3.7	51
146	Mortality in liver transplant recipients with portal vein thrombosis - an updated meta-analysis. <i>Transplant International</i> , 2018, 31, 1318-1329.	1.6	84
147	The Efficacy of CMV Specific Immune Reconstitution is Highly Dependent on Donor/Recipient Serostatus and Type of Solid Organ Transplanted. <i>Transplantation</i> , 2018, 102, S334.	1.0	0
148	The road map toward an hepatitis C virus-free transplant population. <i>American Journal of Transplantation</i> , 2018, 18, 2409-2416.	4.7	5
149	The Lancetâ€EASL Commission on liver diseases in Europe: overcoming unmet needs, stigma, and inequities. <i>Lancet, The</i> , 2018, 392, 621-622.	13.7	19
150	Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study. <i>Hepatology</i> , 2018, 68, 1232-1244.	7.3	26
151	Organ Preservation in Liver Transplantation. <i>Seminars in Liver Disease</i> , 2018, 38, 260-269.	3.6	23
152	Liver transplantation: indications and outcomes. <i>Minerva Gastroenterology</i> , 2018, 64, 124-125.	0.5	1
153	Liver Transplantation for Alcoholic Liver Disease and Hepatocellular Carcinoma. <i>Cancers</i> , 2018, 10, 46.	3.7	26
154	Hemodynamic Evaluation of Nonselective Î²-Blockers in Patients with Cirrhosis and Refractory Ascites. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-7.	1.5	5
155	Continuous infusion of beta-lactam antibiotics in cirrhotic patients with bloodstream infection: results from a prospective multicentre observational study. <i>Journal of Hepatology</i> , 2018, 68, S44-S45.	3.7	2
156	Reversal of hypercoagulability in patients with <scp>HCV</scp>-related cirrhosis after treatment with direct-acting antivirals. <i>Liver International</i> , 2018, 38, 2210-2218.	3.9	39
157	Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis. <i>Digestive and Liver Disease</i> , 2018, 50, 1105-1114.	0.9	41
158	The ILTS Consensus Conference on NAFLD/NASH and liver transplantation. <i>Transplantation</i> , 2018, , 1.	1.0	1
159	Recurrence of Hepatitis B Infection in Liver Transplant Patients Receiving Long-Term Hepatitis B Immunoglobulin Prophylaxis. <i>Annals of Transplantation</i> , 2018, 23, 789-801.	0.9	17
160	Direct-acting antivirals and hepatocellular carcinoma occurrence and recurrence in hepatitis C virus-related liver cirrhosis: fact or finction. <i>Hepatoma Research</i> , 2018, 4, 70.	1.5	3
161	Quality of life and adherence in liver transplant recipients. <i>Minerva Gastroenterology</i> , 2018, 64, 180-186.	0.5	14
162	Nonalcoholic fatty liver disease and liver transplantation - Where do we stand?. <i>World Journal of Gastroenterology</i> , 2018, 24, 1491-1506.	3.3	95

#	ARTICLE	IF	CITATIONS
163	Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study. <i>World Journal of Gastroenterology</i> , 2018, 24, 4403-4411.	3.3	31
164	Management of bacterial infection in the liver transplant candidate. <i>World Journal of Hepatology</i> , 2018, 10, 222-230.	2.0	14
165	Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2017, 49, 440-445.	0.9	66
166	Filling the gap between clinical trials and real life in the treatment of severe HCV recurrence after liver transplantation. <i>Transplant International</i> , 2017, 30, 239-242.	1.6	1
167	Common issues in the management of patients in the waiting list and after liver transplantation. <i>Digestive and Liver Disease</i> , 2017, 49, 241-253.	0.9	23
168	Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis. <i>Journal of Viral Hepatitis</i> , 2017, 24, 858-864.	2.0	11
169	Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients. <i>Transplantation</i> , 2017, 101, S1-S56.	1.0	217
170	International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates. <i>Transplantation</i> , 2017, 101, 945-955.	1.0	76
171	International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients. <i>Transplantation</i> , 2017, 101, 956-967.	1.0	44
172	Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. <i>Journal of Hepatology</i> , 2017, 66, 552-559.	3.7	166
173	Liver Re-transplantation for Hepatic Abscess Due to Hepatic Artery Thrombosis: A Case Report. <i>Transplantation Proceedings</i> , 2017, 49, 736-739.	0.6	0
174	Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals. <i>Liver Transplantation</i> , 2017, 23, 1103-1112.	2.4	46
175	Antibiotic prophylaxis for preventing postorthotopic liver transplant tuberculosis: is there a safe alternative to isoniazid?. <i>Transplant International</i> , 2017, 30, 734-736.	1.6	6
176	Prothrombotic microparticles and risk of portal vein thrombosis in patients with HCV-related liver cirrhosis who underwent DAA antiviral therapy. <i>Digestive and Liver Disease</i> , 2017, 49, e9.	0.9	0
177	Outcome of liver transplant recipients after the first episode of bacterial infection. <i>Digestive and Liver Disease</i> , 2017, 49, e12.	0.9	0
178	Eradication of HCV in patients awaiting liver transplantation does not increase drop-out due to HCC progression. <i>Digestive and Liver Disease</i> , 2017, 49, e47.	0.9	0
179	Emerging players in liver fibrosis regression in a chronic murine model of hepatic injury. <i>Digestive and Liver Disease</i> , 2017, 49, e64.	0.9	0
180	Evolution of liver transplantation for alcoholic liver disease: A single center study. <i>Digestive and Liver Disease</i> , 2017, 49, e240.	0.9	0

#	ARTICLE	IF	CITATIONS
181	Reply. Liver Transplantation, 2017, 23, 1630-1631.	2.4	0
182	Extending transplantation criteria for hepatocellular carcinoma. The Lancet Gastroenterology and Hepatology, 2017, 2, 546-547.	8.1	0
183	Transplantation for acute alcoholic hepatitis. Clinical Liver Disease, 2017, 9, 141-143.	2.1	4
184	Beneficial role of terlipressin in decompensated cirrhotics with spontaneous bacterial peritonitis. European Journal of Gastroenterology and Hepatology, 2017, 29, 366.	1.6	0
185	The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes. Transplant International, 2017, 30, 1253-1265.	1.6	3
186	Polyclonal and monoclonal B lymphocytes response in HCV-infected patients treated with direct-acting antiviral agents. Journal of Viral Hepatitis, 2017, 24, 1168-1176.	2.0	21
187	Current challenges and future directions for liver transplantation. Liver International, 2017, 37, 317-327.	3.9	62
188	Neuropsychiatric performance and treatment of hepatitis C with direct-acting antivirals: a prospective study. BMJ Open Gastroenterology, 2017, 4, e000183.	2.7	9
189	Acute alcoholic hepatitis and liver transplantation: Waiting for Godot. Liver International, 2017, 37, 1408-1408.	3.9	1
190	Prevalent use of combined prophylaxis of hepatitis B after liver transplantation in Italy: results of a national survey in a large cohort. Minerva Gastroenterology, 2017, 64, 1-9.	0.5	3
191	Long term follow-up and outcome of liver transplantation from hepatitis B surface antigen positive donors. World Journal of Gastroenterology, 2017, 23, 2095.	3.3	14
192	Liver transplantation for viral hepatitis in 2015. World Journal of Gastroenterology, 2016, 22, 1570.	3.3	36
193	Therapeutic approaches for portal biliopathy: A systematic review. World Journal of Gastroenterology, 2016, 22, 9909.	3.3	35
194	Liver Transplantation for Alcoholic Liver Disease. Transplantation, 2016, 100, 981-987.	1.0	65
195	Biopsy-proven acute cellular rejection as an efficacy endpoint of randomized trials in liver transplantation: a systematic review and critical appraisal. Transplant International, 2016, 29, 961-973.	1.6	57
196	The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: Results of a randomized, controlled clinical trial. Hepatology, 2016, 63, 1299-1309.	7.3	186
197	HCV eradication is not associated with drop-out due to HCC progression in patients awaiting liver transplantation: A monocentric experience. Digestive and Liver Disease, 2016, 48, e237.	0.9	0
198	Transition of pediatric liver transplanted recipients to Adult Healthcare Service: A single center cohort. Digestive and Liver Disease, 2016, 48, e61.	0.9	0

#	ARTICLE	IF	CITATIONS
199	Laparoscopic ablation and salvage transplantation for patients with hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2016, 48, e24.	0.9	0
200	Circulating microparticles and risk of portal vein thrombosis in patients with liver cirrhosis and hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2016, 48, e37.	0.9	0
201	Coronary microvascular dysfunction in patients with decompensated cirrhosis: Another tool for understanding cirrhotic cardiomyopathy?. <i>Digestive and Liver Disease</i> , 2016, 48, e59.	0.9	0
202	Pancreatic melanoma metastasis diagnosed by endoscopic ultrasound-guided SharkCore biopsy. <i>Endoscopy</i> , 2016, 48, E208-E209.	1.8	5
203	Timing for treatment of HCV recurrence after liver transplantation: the earlier the better. <i>Transplant International</i> , 2016, 29, 694-697.	1.6	4
204	AISF position paper on liver transplantation and pregnancy. <i>Digestive and Liver Disease</i> , 2016, 48, 860-868.	0.9	20
205	The balance between fibrosis and regeneration in chronic liver injury: The role of gender. <i>Digestive and Liver Disease</i> , 2016, 48, e26.	0.9	0
206	Organ allocation for liver transplantation: One size does not fill all. <i>Liver Transplantation</i> , 2016, 22, 715-716.	2.4	0
207	Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma. <i>Transplantation</i> , 2016, 100, 116-125.	1.0	339
208	AISF position paper on liver disease and pregnancy. <i>Digestive and Liver Disease</i> , 2016, 48, 120-137.	0.9	32
209	EASL Clinical Practice Guidelines: Liver transplantation. <i>Journal of Hepatology</i> , 2016, 64, 433-485.	3.7	744
210	Differential timing of oxidative DNA damage and telomere shortening in hepatitis C and B virus-related liver carcinogenesis. <i>Translational Research</i> , 2016, 168, 122-133.	5.0	19
211	Hepatitis C virus and liver transplantation: where do we stand?. <i>Transplant International</i> , 2016, 29, 135-152.	1.6	12
212	New Perspectives on Treatment of Hepatitis B Before and After Liver Transplantation. <i>Annals of Transplantation</i> , 2016, 21, 632-643.	0.9	5
213	Orthotopic Liver Transplantation in Alcoholic Liver Disease Patients. <i>Reviews on Recent Clinical Trials</i> , 2016, 11, 253-259.	0.8	3
214	Rethinking the role of non-selective beta blockers in patients with cirrhosis and portal hypertension. <i>World Journal of Hepatology</i> , 2016, 8, 1012.	2.0	5
215	The era of the new directly acting antivirals: Has the time come for kidney transplant only in compensated cirrhosis?. <i>Transplant International</i> , 2015, 28, 620-621.	1.6	1
216	Umbilical cord mesenchymal stem cells modulate dextran sulfate sodium induced acute colitis in immunodeficient mice. <i>Stem Cell Research and Therapy</i> , 2015, 6, 79.	5.5	49

#	ARTICLE	IF	CITATIONS
217	Severe small bowel pneumatosis in adult heart transplant recipient. <i>Transplant International</i> , 2015, 28, 1002-1004.	1.6	2
218	Age and equity in liver transplantation: An organ allocation model. <i>Liver Transplantation</i> , 2015, 21, 1241-1249.	2.4	28
219	Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation. <i>Transplant International</i> , 2015, 28, 1055-1065.	1.6	7
220	HCC criteria for liver transplantation: Controversies. <i>Liver Transplantation</i> , 2015, 21, S27-S31.	2.4	3
221	Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor. <i>Liver Transplantation</i> , 2015, 21, 1250-1258.	2.4	10
222	Risk Factors for Central Pontine and Extrapontine Myelinolysis After Liver Transplantation. <i>Transplantation</i> , 2015, 99, 1257-1264.	1.0	40
223	Fifteen years and 382 extended right grafts from in situ split livers in a multicenter study: Are these still extended criteria liver grafts?. <i>Liver Transplantation</i> , 2015, 21, 500-511.	2.4	33
224	A Multistep, Consensus-Based Approach to Organ Allocation in Liver Transplantation: Toward a "Blended Principle Model". <i>American Journal of Transplantation</i> , 2015, 15, 2552-2561.	4.7	164
225	Successful pregnancy in Alagille Syndrome. <i>Digestive and Liver Disease</i> , 2015, 47, 86-87.	0.9	12
226	Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: A multicentre study. <i>Journal of Hepatology</i> , 2015, 62, 617-624.	3.7	184
227	Lack of agreement for defining "clinical suspicion of rejection" in liver transplantation: a model to select candidates for liver biopsy. <i>Transplant International</i> , 2015, 28, 455-464.	1.6	29
228	A new prognostic model to predict dropout from the waiting list in cirrhotic candidates for liver transplantation with MELD score ≤ 18. <i>Liver International</i> , 2015, 35, 184-191.	3.9	17
229	Assessment of Bleeding Risk in Patients with Cirrhosis. <i>Current Hepatology Reports</i> , 2015, 14, 9-18.	0.9	3
230	Head and neck and esophageal cancers after liver transplant: results from a multicenter cohort study. Italy, 1997-2010. <i>Transplant International</i> , 2015, 28, 841-848.	1.6	13
231	Reply to: Time to resize the role of everolimus as treatment of hepatocellular carcinoma recurrence after liver transplant. <i>Transplant International</i> , 2015, 28, 503-504.	1.6	1
232	Orthotopic Liver Transplantation in Non-Alcoholic Fatty Liver Disease Patients. <i>Reviews on Recent Clinical Trials</i> , 2015, 9, 210-216.	0.8	11
233	Neoplastic disease after liver transplantation: Focus on <i>de novo</i> neoplasms. <i>World Journal of Gastroenterology</i> , 2015, 21, 8753.	3.3	62
234	Markers of acute rejection and graft acceptance in liver transplantation. <i>World Journal of Gastroenterology</i> , 2015, 21, 1061.	3.3	57

#	ARTICLE	IF	CITATIONS
235	Acute alcoholic hepatitis, end stage alcoholic liver disease and liver transplantation: An Italian position statement. <i>World Journal of Gastroenterology</i> , 2014, 20, 14642.	3.3	66
236	Renal Function Deterioration Is Higher Within The First Year After Liver Transplantation: Results of The Italian Cross-Sectional, Multicenter Study (SURF).. <i>Transplantation</i> , 2014, 98, 759-760.	1.0	0
237	Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. <i>Transplant International</i> , 2014, 27, 1039-1049.	1.6	145
238	Can liver transplantation provide the statistical cure?. <i>Liver Transplantation</i> , 2014, 20, 210-217.	2.4	10
239	Sorafenib use in the transplant setting. <i>Liver Transplantation</i> , 2014, 20, 1021-1028.	2.4	12
240	Management of infections in cirrhotic patients: Report of a Consensus Conference. <i>Digestive and Liver Disease</i> , 2014, 46, 204-212.	0.9	40
241	P973 VALUE-BASED APPROACH TO HEPATOCELLULAR CARCINOMA: OUTCOME INDICATORS TESTED IN A LARGE MULTICENTER STUDY (VBMH STUDY). <i>Journal of Hepatology</i> , 2014, 60, S399.	3.7	0
242	Management of infections pre- and post-liver transplantation: Report of an AISF consensus conference. <i>Journal of Hepatology</i> , 2014, 60, 1075-1089.	3.7	77
243	Survival Benefit of Transplantation for Recurrence of Hepatocellular Carcinoma After Liver Resection. <i>Transplantation Proceedings</i> , 2014, 46, 2287-2289.	0.6	5
244	Effects of non-selective β -blockers on hemodynamics and paracentesis induced circulatory dysfunction in patients with cirrhosis undergoing large volume paracentesis. <i>Digestive and Liver Disease</i> , 2014, 46, e138.	0.9	0
245	Potential net health benefit of pre-transplant Sofosbuvir to prevent recurrence of HCV infection after liver transplantation: A multicenter, cohort model study. <i>Digestive and Liver Disease</i> , 2014, 46, e132-e133.	0.9	1
246	A rare combination of type 3 autoimmune polyendocrine syndrome (APS-3) or multiple autoimmune syndrome (MAS-3). <i>Autoimmunity Highlights</i> , 2014, 5, 27-31.	3.9	20
247	Physical Activity in Solid Organ Transplant Recipients: Organizational Aspects and Preliminary Results of the Italian Project. <i>Transplantation Proceedings</i> , 2014, 46, 2345-2349.	0.6	26
248	Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C. <i>Digestive and Liver Disease</i> , 2014, 46, 440-445.	0.9	3
249	Effects of Non-Selective β -Blockers on hemodynamic and Paracentesis Induced Circulatory Dysfunction in cirrhotics undergoing large volume paracentesis. <i>Digestive and Liver Disease</i> , 2014, 46, e59.	0.9	0
250	A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list. <i>Journal of Hepatology</i> , 2014, 60, 290-297.	3.7	89
251	Hepatitis C virus infection in end-stage renal disease and kidney transplantation. <i>Transplant International</i> , 2014, 27, 877-891.	1.6	23
252	White Paper of Italian Gastroenterology: Delivery of services for digestive diseases in Italy: Weaknesses and strengths. <i>Digestive and Liver Disease</i> , 2014, 46, 579-589.	0.9	40

#	ARTICLE	IF	CITATIONS
253	A Prospective Policy Development to Increase Split-Liver Transplantation for 2 Adult Recipients. <i>Annals of Surgery</i> , 2014, 259, 157-165.	4.2	53
254	Female gender in the setting of liver transplantation. <i>World Journal of Transplantation</i> , 2014, 4, 229.	1.6	30
255	Adult Liver Stem Cells. <i>Pancreatic Islet Biology</i> , 2014, , 319-338.	0.3	0
256	Use of Anti-HCV Positive Grafts in Liver Transplantation. , 2014, , 107-116.		0
257	Risk of renal cell cancer in people immunodepressed after solid organ transplant: Results from an Italian multicenter cohort study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 422-422.	1.6	0
258	Hepatitis C virus infection in end stage renal disease and after kidney transplant. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2014, 23, 340-2.	0.9	1
259	Skills and Requirements of a Transplant Hepatologist: Board Certification of the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2013, 45, 992-994.	0.9	3
260	Cyanoacrylate injection to treat recurrent bleeding from Dieulafoy's lesion. <i>Gastrointestinal Endoscopy</i> , 2013, 78, 964-965.e2.	1.0	4
261	Liver abnormalities and endocrine diseases. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2013, 27, 553-563.	2.4	75
262	Interaction between calcineurin inhibitors and IL-28B rs12979860 C>T polymorphism and response to treatment for post-transplant recurrent hepatitis C. <i>Digestive and Liver Disease</i> , 2013, 45, 927-932.	0.9	5
263	Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers. <i>Transplant International</i> , 2013, 26, 281-289.	1.6	7
264	Liver transplantation for HBV-related cirrhosis in Europe: An ELTR study on evolution and outcomes. <i>Journal of Hepatology</i> , 2013, 58, 287-296.	3.7	99
265	108 A NOVEL MODEL OF PRIORITY ASSESSMENT FOR PATIENTS WITH AND WITHOUT HEPATOCELLULAR CARCINOMA ON A COMMON LIVER TRANSPLANT WAITING LIST: A MULTICENTRE, COHORT STUDY. <i>Journal of Hepatology</i> , 2013, 58, S48.	3.7	2
266	Use of Grafts From Anti-HBcâ€“Positive Donors in Liver Transplantation: A 5-Year, Single-Center Experience. <i>Transplantation Proceedings</i> , 2013, 45, 2707-2710.	0.6	8
267	Long-term quality of life for transplant recipients. <i>Liver Transplantation</i> , 2013, 19, S40-S43.	2.4	20
268	Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: Evidence from the Liver Match cohort study. <i>Journal of Hepatology</i> , 2013, 58, 715-723.	3.7	44
269	Balancing Utility and Need by Means of Donor-to-Recipient Matching: A Challenging Problem. <i>American Journal of Transplantation</i> , 2013, 13, 522-523.	4.7	25
270	Model for end-stage liver disease-sodium and survival benefit in liver transplantation. <i>Transplant International</i> , 2013, 26, 138-144.	1.6	6

#	ARTICLE	IF	CITATIONS
271	Influence of Age and Gender Before and After Liver Transplantation. <i>Liver Transplantation</i> , 2013, 19, 122-134.	2.4	55
272	Can we match donors and recipients in a cost-effective way?. <i>Transplant International</i> , 2013, 26, 1061-1062.	1.6	2
273	Liver transplantation for alcoholic liver disease. <i>Clinical Liver Disease</i> , 2013, 2, 92-95.	2.1	9
274	Cavoportal Hemitransposition Associated to Portoportal Anastomosis for Liver Transplant in Portomesenteric Thrombosis. <i>Transplantation</i> , 2013, 96, e69-e71.	1.0	1
275	Who Fares Worse After Liver Transplantation? Impact of Donor and Recipient Variables on Outcome. <i>Transplantation</i> , 2013, 95, 1528-1534.	1.0	17
276	Skin Cancer and Other Cutaneous Disorders in Liver Transplant Recipients. <i>Acta Dermato-Venereologica</i> , 2012, 92, 411-415.	1.3	34
277	Management of Nonneoplastic Portal Vein Thrombosis in the Setting of Liver Transplantation. <i>Transplantation</i> , 2012, 94, 1145-1153.	1.0	183
278	Liver transplantation for hepatocellular carcinoma in clinical practice. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 195-202.	1.6	15
279	MELD-Na and Survival Benefit in Liver Transplantation. <i>Transplantation</i> , 2012, 94, 677.	1.0	0
280	Can the Un-Sustainable Match Be Identified in Liver Transplant Population? Evidencies from the Italian Donor-2-Recipient D-Meld Study. <i>Transplantation</i> , 2012, 94, 567.	1.0	0
281	Trends in liver transplantation 2011. <i>Journal of Hepatology</i> , 2012, 56, S101-S111.	3.7	15
282	EASL Clinical Practical Guidelines: Management of Alcoholic Liver Disease. <i>Journal of Hepatology</i> , 2012, 57, 399-420.	3.7	602
283	Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. <i>Liver International</i> , 2012, 32, 919-927.	3.9	284
284	Anticoagulation for the treatment of thrombotic complications in patients with cirrhosis. <i>Liver International</i> , 2012, 32, 1465-1476.	3.9	55
285	The adolescent and liver transplantation. <i>Journal of Hepatology</i> , 2012, 56, 714-722.	3.7	29
286	Liver transplantation for acute liver failure in Europe: Outcomes over 20years from the ELTR database. <i>Journal of Hepatology</i> , 2012, 57, 288-296.	3.7	236
287	Liver transplantation for unresectable hepatocellular carcinoma in normal livers. <i>Journal of Hepatology</i> , 2012, 57, 297-305.	3.7	49
288	Systemic administration of a novel human umbilical cord mesenchymal stem cells population accelerates the resolution of acute liver injury. <i>BMC Gastroenterology</i> , 2012, 12, 88.	2.0	58

#	ARTICLE	IF	CITATIONS
289	Antiviral therapy and fibrosis progression in patients with mild-to-moderate hepatitis C recurrence after liver transplantation. A randomized controlled study. <i>Digestive and Liver Disease</i> , 2012, 44, 603-609.	0.9	12
290	Sorafenib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplantation?. <i>Transplantation Proceedings</i> , 2012, 44, 1989-1991.	0.6	27
291	http://www.D-MELD.com , the Italian survival calculator to optimize donor to recipient matching and to identify the unsustainable matches in liver transplantation. <i>Transplant International</i> , 2012, 25, 294-301.	1.6	26
292	Development and validation of a questionnaire evaluating the impact of hepatitis B immune globulin prophylaxis on the quality of life of liver transplant recipients. <i>Liver Transplantation</i> , 2012, 18, 332-339.	2.4	17
293	Liver Match, a prospective observational cohort study on liver transplantation in Italy: Study design and current practice of donor-to-recipient matching. <i>Digestive and Liver Disease</i> , 2011, 43, 155-164.	0.9	69
294	Tips for portal vein thrombosis (pvt) in cirrhosis: Not only unblocking a pipe. <i>Journal of Hepatology</i> , 2011, 55, 945-946.	3.7	24
295	Infections and Organ Transplantation: New Challenges for Prevention and Treatment of Hepatitis C Virus. <i>Transplantation Proceedings</i> , 2011, 43, 2455-2456.	0.6	1
296	Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. <i>Lancet Oncology</i> , The, 2011, 12, 654-662.	10.7	135
297	Facing HCV recurrence after liver transplantation: antiviral therapy response and clinical outcome. <i>Digestive and Liver Disease Supplements</i> , 2011, 5, 30-35.	0.2	0
298	523 PROTRACTED ANTIVIRAL TREATMENT BEYOND CONVENTIONAL TIME LIMITS IMPROVES SURVIVAL IN NON-RESPONDERS TO INTERFERON+RIBAVIRIN ADMINISTERED FOR HCV RECURRENCE AFTER LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , 2011, 54, S214-S215.	3.7	0
299	Long-Term Follow-Up and Outcome of Liver Transplantation From Anti-Hepatitis C Virus-Positive Donors: A European Multicentric Case-Control Study. <i>Transplantation</i> , 2011, 91, 1265-1272.	1.0	79
300	Antiviral treatment for HCV recurrence after liver transplantation: when, how much and for how long?. <i>Future Virology</i> , 2011, 6, 1179-1186.	1.8	2
301	A novel approach to severe acute pancreatitis in sequential liver-kidney transplantation: the first report on the application of VAC therapy. <i>Transplant International</i> , 2011, 24, e23-e27.	1.6	5
302	Balancing Donor and Recipient Risk Factors in Liver Transplantation: The Value of D-MELD With Particular Reference to HCV Recipients. <i>American Journal of Transplantation</i> , 2011, 11, 2724-2736.	4.7	86
303	Management of Hepatitis C Virus Infection Recurrence After Liver Transplantation: An Overview. <i>Transplantation Proceedings</i> , 2011, 43, 291-295.	0.6	21
304	Nonadherent Behaviors After Solid Organ Transplantation. <i>Transplantation Proceedings</i> , 2011, 43, 318-323.	0.6	68
305	Donor-Model for End-Stage Liver Disease and Donor-Recipient Matching in Liver Transplantation. <i>Transplantation Proceedings</i> , 2011, 43, 974-976.	0.6	14
306	Risk Factors in Liver Retransplantation: A Single-Center Experience. <i>Transplantation Proceedings</i> , 2011, 43, 1110-1113.	0.6	28

#	ARTICLE	IF	CITATIONS
307	Microwave Thermal Ablation for Hepatocarcinoma: Six Liver Transplantation Cases. <i>Transplantation Proceedings</i> , 2011, 43, 1091-1094.	0.6	26
308	Adherence in liver transplant recipients. <i>Liver Transplantation</i> , 2011, 17, 760-770.	2.4	138
309	Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma: A review and consensus statement. <i>Liver Transplantation</i> , 2011, 17, S81-S89.	2.4	51
310	De Novo Autoimmune Hepatitis after Liver Transplantation. <i>Seminars in Liver Disease</i> , 2011, 31, 071-081.	3.6	53
311	Molecular Refinement of Clinical Staging in Hepatocellular Carcinoma Patients Evaluated for Potentially Curative Therapies. <i>PLoS ONE</i> , 2011, 6, e23093.	2.5	4
312	Neuropsychological alterations in hepatitis C infection: The role of inflammation. <i>World Journal of Gastroenterology</i> , 2011, 17, 3369.	3.3	69
313	Therapeutic application of stem cells in gastroenterology: An up-date. <i>World Journal of Gastroenterology</i> , 2011, 17, 3870.	3.3	17
314	Sexual Dysfunction in Chronic Liver Disease: Is Liver Transplantation an Effective Cure?. <i>Transplantation</i> , 2010, 89, 1425-1429.	1.0	48
315	Response to Therapy as a Criterion for Awarding Priority to Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation. <i>Annals of Surgical Oncology</i> , 2010, 17, 2290-2302.	1.5	66
316	A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. <i>BMC Cancer</i> , 2010, 10, 190.	2.6	146
317	Liver Transplantation for Alcoholic Liver Disease in Europe: A Study from the ELTR (European Liver) Tj ETQq1 1 0.784314 rgBT /Overlook	4.7	286
318	Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: A cost-benefit analysis while awaiting data on sorafenib safety. <i>Hepatology</i> , 2010, 51, 165-173.	7.3	93
319	Risk factors for portal venous thrombosis after splenectomy in patients with cirrhosis and portal hypertension (<i>Br J Surg</i> 2010; 97: 910-916). <i>British Journal of Surgery</i> , 2010, 97, 1452-1452.	0.3	3
320	Primary liver transplantation for autoimmune hepatitis: A comparative analysis of the European Liver Transplant Registry. <i>Liver Transplantation</i> , 2010, 16, NA-NA.	2.4	38
321	Bax Inhibitor-1 down-regulation in the progression of chronic liver diseases. <i>BMC Gastroenterology</i> , 2010, 10, 35.	2.0	15
322	Comparison of de novo tumours after liver transplantation with incidence rates from Italian cancer registries. <i>Digestive and Liver Disease</i> , 2010, 42, 55-60.	0.9	59
323	Practice guidelines for the treatment of hepatitis C: Recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. <i>Digestive and Liver Disease</i> , 2010, 42, 81-91.	0.9	56
324	The survival benefit of liver transplantation in hepatocellular carcinoma patients. <i>Digestive and Liver Disease</i> , 2010, 42, 642-649.	0.9	42

#	ARTICLE	IF	CITATIONS
325	Estimation of the Harm to the Waiting List as a Crucial Factor in the Selection of Patients With Hepatocellular Carcinoma for Liver Transplantation. <i>Transplantation Proceedings</i> , 2010, 42, 1194-1196.	0.6	18
326	Fibrosis Progression and the Pros and Cons of Antiviral Therapy for Hepatitis C Virus Recurrence After Liver Transplantation: A Review. <i>Transplantation Proceedings</i> , 2010, 42, 2223-2225.	0.6	10
327	473 NON ADHERENCE TO MEDICAL PRESCRIPTIONS IN LIVER TRANSPLANTATION: A PROSPECTIVE LONGITUDINAL STUDY. <i>Journal of Hepatology</i> , 2010, 52, S191-S192.	3.7	1
328	Hepatitis C. <i>Seminars in Liver Disease</i> , 2009, 29, 053-065.	3.6	50
329	The Impact of Hepatitis C and Biliary Complications on Patient and Graft Survival Following Liver Transplantation. <i>American Journal of Transplantation</i> , 2009, 9, 1398-1405.	4.7	22
330	Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation. <i>Liver Transplantation</i> , 2009, 15, 390-399.	2.4	39
331	Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients. <i>Liver Transplantation</i> , 2009, 15, 619-628.	2.4	41
332	Sexual dysfunction after liver transplantation. <i>Liver Transplantation</i> , 2009, 15, S50-S56.	2.4	31
333	Anticoagulation for portal vein thrombosis in cirrhotic patients should be always considered. <i>Internal and Emergency Medicine</i> , 2009, 4, 161-162.	2.0	41
334	Neurologic complications after solid organ transplantation. <i>Transplant International</i> , 2009, 22, 269-278.	1.6	163
335	Study of the microcirculation in hDAF transgenic rat livers xenoperfused with human blood. <i>Xenotransplantation</i> , 2009, 16, 83-90.	2.8	2
336	People's attitude toward xenotransplantation: affective reactions and the influence of the evaluation context. <i>Xenotransplantation</i> , 2009, 16, 129-134.	2.8	13
337	β-blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. <i>Liver International</i> , 2009, 29, 1189-1193.	3.9	207
338	Risk of Kaposi Sarcoma after Solid-Organ Transplantation: Multicenter Study in 4767 Recipients in Italy, 1970-2006. <i>Transplantation Proceedings</i> , 2009, 41, 1227-1230.	0.6	36
339	Prospective Validation of a New Priority Allocation Model for Liver Transplant Candidates: An Interim Analysis. <i>Transplantation Proceedings</i> , 2009, 41, 1092-1095.	0.6	12
340	Validation of the BCLC Prognostic System in Surgical Hepatocellular Cancer Patients. <i>Transplantation Proceedings</i> , 2009, 41, 1260-1263.	0.6	51
341	Alcohol Abuse and De Novo Tumors in Liver Transplantation. <i>Transplantation Proceedings</i> , 2009, 41, 1310-1312.	0.6	13
342	De Novo Tumors Are a Major Cause of Late Mortality After Orthotopic Liver Transplantation. <i>Transplantation Proceedings</i> , 2009, 41, 1303-1305.	0.6	46

#	ARTICLE	IF	CITATIONS
343	Long-Term Evaluation of Cognitive Function and Cerebral Metabolism in Liver Transplanted Patients. <i>Transplantation Proceedings</i> , 2009, 41, 1295-1296.	0.6	30
344	Progression of Hepatocellular Carcinoma Before Liver Transplantation: Dropout or Liver Transplantation?. <i>Transplantation Proceedings</i> , 2009, 41, 1264-1267.	0.6	20
345	Prognostic Evaluation of the Donor Risk Index Among a Prospective Cohort of Italian Patients Undergoing Liver Transplantation. <i>Transplantation Proceedings</i> , 2009, 41, 1096-1098.	0.6	11
346	Factors influencing renal function after liver transplantation. Results from the MOST, an international observational study. <i>Digestive and Liver Disease</i> , 2009, 41, 350-356.	0.9	76
347	The ethical equipoise in living and deceased donor liver transplantation: Towards decision processes based on mathematical models. <i>Digestive and Liver Disease</i> , 2009, 41, A16-A17.	0.9	0
348	Evaluation of graft and recipient risk factors in liver transplantation. <i>Digestive and Liver Disease Supplements</i> , 2009, 3, 108-111.	0.2	1
349	788 INTERMEDIATE STAGE HEPATOCELLULAR CARCINOMA (HCC): TO TACE OR NOT TO TACE?. <i>Journal of Hepatology</i> , 2009, 50, S288-S289.	3.7	1
350	Bile duct stones and casts after liver transplantation: Different entities but similar prevention strategy?. <i>Liver Transplantation</i> , 2008, 14, 1400-1403.	2.4	8
351	Report of the Paris consensus meeting on expanded criteria donors in liver transplantation. <i>Liver Transplantation</i> , 2008, 14, 1694-1707.	2.4	257
352	Torque Teno virus: any pathological role in liver transplanted patients?. <i>Transplant International</i> , 2008, 21, 972-979.	1.6	45
353	Strengthening acceptance for xenotransplantation: the case of attraction effect. <i>Xenotransplantation</i> , 2008, 15, 159-163.	2.8	22
354	Experimental hepatology applied to stem cells. <i>Digestive and Liver Disease</i> , 2008, 40, 54-61.	0.9	9
355	HCV infection in haemodialysed patients: A role for serum IL-10 and TGF- β 1 in liver damage?. <i>Digestive and Liver Disease</i> , 2008, 40, 827-833.	0.9	3
356	HCV Histological Recurrence and Survival Following Liver Transplantation in Patients With and Without Hepatocellular Carcinoma. <i>Transplantation Proceedings</i> , 2008, 40, 1974-1975.	0.6	4
357	Microvascular Autonomic Dysfunction May Justify False-Positive Stress Myocardial Perfusion Imaging in Patients With Liver Cirrhosis Undergoing Liver Transplantation. <i>Transplantation Proceedings</i> , 2008, 40, 1916-1917.	0.6	24
358	Transcatheter Arterial Chemoembolization (TACE) in Hepatocellular Carcinoma (HCC): The Role of Angiogenesis and Invasiveness. <i>American Journal of Gastroenterology</i> , 2008, 103, 914-921.	0.4	429
359	Post-Transplant Lymphoproliferative Disorders after Heart or Kidney Transplantation at a Single Centre: Presentation and Response to Treatment. <i>Acta Haematologica</i> , 2008, 120, 36-46.	1.4	9
360	ABO Blood Group-Related Waiting List Disparities in Liver Transplant Candidates: Effect of the MELD Adoption. <i>Transplantation</i> , 2008, 85, 844-849.	1.0	15

#	ARTICLE	IF	CITATIONS
361	Hepatitis C Infection in Patients with Chronic Kidney Disease. <i>International Journal of Artificial Organs</i> , 2008, 31, 15-33.	1.4	13
362	Micronuclei and broken eggs in human liver carcinogenesis. <i>Anticancer Research</i> , 2008, 28, 2507-11.	1.1	11
363	Effect of penicillamine and zinc on iron metabolism in Wilson's disease. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 1495-1500.	1.5	30
364	Combined Liver and Kidney Transplantation: Analysis of Padova Experience. <i>Transplantation Proceedings</i> , 2007, 39, 1933-1935.	0.6	10
365	Algorithm for Prioritization of Patients on the Waiting List for Liver Transplantation. <i>Transplantation Proceedings</i> , 2007, 39, 1855-1856.	0.6	4
366	The Concept of Quality of Life in Organ Transplantation. <i>Transplantation Proceedings</i> , 2007, 39, 2285-2287.	0.6	32
367	Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. <i>European Journal of Cancer</i> , 2007, 43, 2117-2123.	2.8	127
368	Different neurological outcome of liver transplantation for Wilson's disease in two homozygotic twins. <i>Clinical Neurology and Neurosurgery</i> , 2007, 109, 71-75.	1.4	41
369	Influence of steroids on HCV recurrence after liver transplantation: A prospective study. <i>Journal of Hepatology</i> , 2007, 47, 793-798.	3.7	104
370	The transjugular route: The key hole to the liver world. <i>Digestive and Liver Disease</i> , 2007, 39, 105-116.	0.9	23
371	Prophylaxis and treatment of hepatitis B in immunocompromised patients. <i>Digestive and Liver Disease</i> , 2007, 39, 397-408.	0.9	197
372	Compliance to medical regimen in patients before and after liver transplantation: Are there any predictive factors?. <i>Digestive and Liver Disease</i> , 2007, 39, A38-A39.	0.9	0
373	Veno occlusive disease: Update on clinical management. <i>World Journal of Gastroenterology</i> , 2007, 13, 3918.	3.3	79
374	A randomized study comparing ligation with propranolol for primary prophylaxis of variceal bleeding in candidates for liver transplantation. <i>Liver Transplantation</i> , 2007, 13, 1272-1278.	2.4	63
375	Liver transplantation for HCV cirrhosis: Improved survival in recent years and increased severity of recurrent disease in female recipients: Results of a long term retrospective study. <i>Liver Transplantation</i> , 2007, 13, 733-740.	2.4	124
376	Partial hepatectomy as first-line treatment for patients with hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2007, 95, 213-220.	1.7	28
377	Quality of life following organ transplantation. <i>Transplant International</i> , 2007, 20, 397-409.	1.6	103
378	Normal cortical regional cerebral blood flow justifies the normal neuropsychological performance in patients with cholestatic liver disease. <i>Psychiatry and Clinical Neurosciences</i> , 2007, 61, 209-210.	1.8	2

#	ARTICLE	IF	CITATIONS
379	Hepatitis C virus: from oxygen free radicals to hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2007, 14, 821-829.	2.0	49
380	Intention-to-Treat Analysis of Liver Transplantation in Selected, Aggressively Treated HCC Patients Exceeding the Milan Criteria. <i>American Journal of Transplantation</i> , 2007, 7, 972-981.	4.7	111
381	A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. <i>Journal of Hepatology</i> , 2007, 46, 1009-1017.	3.7	96
382	HLA-DRB1 Donor-Recipient Mismatch Affects the Outcome of Hepatitis C Disease Recurrence After Liver Transplantation. <i>Gastroenterology</i> , 2006, 130, 695-702.	1.3	29
383	Should donors and recipients be matched in liver transplantation?. <i>Journal of Hepatology</i> , 2006, 45, 488-494.	3.7	22
384	Antiviral Therapy for Hepatitis C Virus Recurrence Following Liver Transplantation: Long-Term Results From a Single Center Experience. <i>Transplantation Proceedings</i> , 2006, 38, 1127-1130.	0.6	20
385	Immunosuppression and Cancer: A Comparison of Risks in Recipients of Organ Transplants and in HIV-Positive Individuals. <i>Transplantation Proceedings</i> , 2006, 38, 3533-3535.	0.6	41
386	Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection?. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 1065-1070.	1.6	51
387	Incidence of Second Primary Cancer in Transplanted Patients. <i>Transplantation</i> , 2006, 81, 982-985.	1.0	10
388	Understanding of and attitudes to organ donation and transplantation: a survey among Italian university students. <i>Clinical Transplantation</i> , 2006, 20, 307-312.	1.6	24
389	Understanding of and attitude to xenotransplantation among Italian university students: impact of a 3-yr university course. <i>Xenotransplantation</i> , 2006, 13, 264-271.	2.8	17
390	CD105(+) cells from Wharton's jelly show in vitro and in vivo myogenic differentiative potential. <i>International Journal of Molecular Medicine</i> , 2006, 18, 1089.	4.0	73
391	Protocol liver biopsies in long-term management of patients transplanted for hepatitis B-related liver disease. <i>World Journal of Gastroenterology</i> , 2006, 12, 1706.	3.3	19
392	New insights into the coagulopathy of liver disease and liver transplantation. <i>World Journal of Gastroenterology</i> , 2006, 12, 7725.	3.3	151
393	Metabolic activity of rat hepatocytes cultured on homologous acellular matrix and transplanted into Gunn rats. <i>International Journal of Molecular Medicine</i> , 2006, 18, 837-42.	4.0	4
394	CD105(+) cells from Wharton's jelly show in vitro and in vivo myogenic differentiative potential. <i>International Journal of Molecular Medicine</i> , 2006, 18, 1089-96.	4.0	143
395	Kaposi's Sarcoma in Transplant and HIV-infected Patients: An Epidemiologic Study in Italy and France. <i>Transplantation</i> , 2005, 80, 1699-1704.	1.0	50
396	Liver transplantation in alcoholic patients. <i>Transplant International</i> , 2005, 18, 491-498.	1.6	50

#	ARTICLE	IF	CITATIONS
397	Vanishing bile duct syndrome. <i>British Journal of Surgery</i> , 2005, 79, 604-605.	0.3	10
398	Successful pregnancy in a liver transplant recipient treated with lamivudine for de novo hepatitis B in the graft. <i>Transplant International</i> , 2005, 17, 730-734.	1.6	10
399	Isoniazid-related fulminant hepatic failure in a child: assessment of the native liver's early regeneration after auxiliary partial orthotopic liver transplantation. <i>Transplant International</i> , 2005, 17, 713-716.	1.6	11
400	Changing Attitude to Organ Donation and Transplantation in University Students During the Years of Medical School in Italy. <i>Transplantation Proceedings</i> , 2005, 37, 547-550.	0.6	71
401	Neuropsychological and Neurophysiological Evaluation in Cirrhotic Patients With Minimal Hepatic Encephalopathy Undergoing Liver Transplantation. <i>Transplantation Proceedings</i> , 2005, 37, 1104-1107.	0.6	24
402	Comparison Between Nifedipine and Carvedilol in the Treatment of de novo Arterial Hypertension After Liver Transplantation: Preliminary Results of a Controlled Clinical Trial. <i>Transplantation Proceedings</i> , 2005, 37, 1245-1247.	0.6	9
403	Is osteoporosis a peculiar association with primary biliary cirrhosis?. <i>World Journal of Gastroenterology</i> , 2005, 11, 5347.	3.3	19
404	Longitudinal prospective study on quality of life and psychological distress before and one year after liver transplantation. <i>Acta Gastro-Enterologica Belgica</i> , 2005, 68, 19-25.	1.0	7
405	Understanding of and attitudes to xenotransplantation: a survey among Italian university students. <i>Xenotransplantation</i> , 2004, 11, 133-140.	2.8	36
406	Isoniazid-related fulminant hepatic failure in a child: assessment of the native liver's early regeneration after auxiliary partial orthotopic liver transplantation. <i>Transplant International</i> , 2004, 17, 713-716.	1.6	2
407	Successful pregnancy in a liver transplant recipient treated with lamivudine for de novo hepatitis B in the graft. <i>Transplant International</i> , 2004, 17, 730-734.	1.6	0
408	Growth hormone/insulin-like growth factor 1 axis recovery after liver transplantation: A preliminary prospective study. <i>Liver Transplantation</i> , 2004, 10, 692-698.	2.4	15
409	A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. <i>Gastroenterology</i> , 2004, 126, 955-963.	1.3	405
410	Clinical significance of alpha-fetoprotein mRNA in blood of patients with hepatocellular carcinoma. <i>Clinica Chimica Acta</i> , 2004, 347, 129-138.	1.1	32
411	The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available?. <i>Journal of Hepatology</i> , 2004, 40, 124-131.	3.7	161
412	Liver Transplantation for the Treatment of Moderately or Well-Differentiated Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2004, 239, 150-159.	4.2	289
413	Double-Blind Comparison of Hepatitis C Histological Recurrence Rate in HCV+ Liver Transplant Recipients Given Basiliximab+Steroids or Basiliximab+Placebo, in addition to Cyclosporine and Azathioprine. <i>Transplantation</i> , 2004, 78, 1488-1495.	1.0	90
414	Does liver-disease aetiology have a role in cerebral blood-flow alterations in liver cirrhosis?. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 885-890.	1.6	21

#	ARTICLE	IF	CITATIONS
415	Acellular liver matrix improves the survival and functions of isolated rat hepatocytes cultured in vitro. <i>International Journal of Molecular Medicine</i> , 2004, 14, 511-5.	4.0	17
416	The role of the steatosis of the donor graft on histological features after liver transplantation (LT). <i>Gastroenterology</i> , 2003, 124, A691.	1.3	0
417	Predictive factors of HCV recurrence after liver transplantation (OLTx). <i>Gastroenterology</i> , 2003, 124, A731.	1.3	0
418	New insight in the biologic support of rat hepatocytes in primary culture. <i>Gastroenterology</i> , 2003, 124, A123.	1.3	0
419	Adjuvant chemotherapy for transplanted hepatocellular carcinoma patients: impact on survival or HCV recurrence timing. <i>Transplantation Proceedings</i> , 2003, 35, 2991-2994.	0.6	18
420	Macroenzymes: too often overlooked. <i>Journal of Hepatology</i> , 2003, 38, 119.	3.7	19
421	Histology predicts cirrhotic evolution of post transplant hepatitis C. <i>Gut</i> , 2002, 50, 697-700.	12.1	65
422	Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2)1. <i>Transplantation</i> , 2002, 73, 953-959.	1.0	178
423	Combined liver-kidney transplantation in a 15-year-old boy with alpha1-antitrypsin deficiency. <i>Journal of Hepatology</i> , 2002, 36, 565-568.	3.7	20
424	Is osteopenia a peculiar association with primary biliary cirrhosis (PBC)? <i>Journal of Hepatology</i> , 2002, 36, 174.	3.7	0
425	Alfa-IFN (N3) plus ribavirin treatment in HCV recurrence after liver transplantation (OLT). <i>Journal of Hepatology</i> , 2002, 36, 192-193.	3.7	0
426	Homologous acellular matrix (HAM): a new support for hepatocyte culture. <i>Journal of Hepatology</i> , 2002, 36, 218-219.	3.7	51
427	Frontal cerebral blood flow is impaired in patients with heart transplantation. <i>Transplant International</i> , 2002, 15, 459-462.	1.6	7
428	Frontal cerebral blood flow is impaired in patients with heart transplantation. <i>Transplant International</i> , 2002, 15, 459-62.	1.6	4
429	Histological features after liver transplantation in alcoholic cirrhotics. <i>Journal of Hepatology</i> , 2001, 34, 716-722.	3.7	90
430	Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. <i>Journal of Hepatology</i> , 2001, 34, 888-894.	3.7	144
431	HBV and HCV infections in heart transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2001, 20, 718-724.	0.6	45
432	Functional and morphological graft monitoring after liver transplantation. <i>Clinica Chimica Acta</i> , 2001, 310, 17-23.	1.1	13

#	ARTICLE	IF	CITATIONS
433	Physiological and clinical implications of proANP(1-98) circulating levels in the perioperative phase of liver transplantation. <i>Clinica Chimica Acta</i> , 2001, 310, 39-48.	1.1	5
434	GH/GHBP changes in the perioperative course of liver transplantation: pathophysiologic and clinical implications. <i>Transplantation Proceedings</i> , 2001, 33, 1390-1392.	0.6	1
435	Myocardial perfusion scintigraphy in patients with liver cirrhosis evaluated for orthotopic liver transplantation. <i>Transplantation Proceedings</i> , 2001, 33, 1447-1448.	0.6	7
436	Natural \pm -IFN in HCV recurrence after liver transplantation. <i>Transplantation Proceedings</i> , 2001, 33, 1457-1458.	0.6	8
437	Histological features of donor grafts for orthotopic liver transplantation. <i>Transplantation Proceedings</i> , 2001, 33, 1177-1178.	0.6	1
438	Bone Metabolism and Gonad Function in Male Patients Undergoing Liver Transplantation: A Two-Year Longitudinal Study. <i>Osteoporosis International</i> , 2001, 12, 749-754.	3.1	64
439	Warm Hepatic Ischemia in Pigs: Effects of L-Arginine and Oligotide Treatment. <i>Journal of Investigative Surgery</i> , 2001, 14, 303-312.	1.3	8
440	Fulminant hepatic failure: the issue of patient selection for hazardous liver assistance. <i>Transplantation Proceedings</i> , 2000, 32, 2719-2722.	0.6	1
441	Role of hepatotropic viruses in the development of lymphoproliferative disorders in organ transplant recipient. <i>Gastroenterology</i> , 2000, 118, A753.	1.3	0
442	Liver transplantation in Italy: current status. <i>Digestive and Liver Disease</i> , 2000, 32, 249-256.	0.9	23
443	Resting energy-expenditure (REE) in cirrhotic patients: Role of plasma concentrations of leptin and tumor necrosis factor- α (TNF- α). <i>Gastroenterology</i> , 2000, 118, A1065.	1.3	0
444	The impact of liver disease and medical complications on quality of life and psychological distress before and after liver transplantation. <i>Journal of Hepatology</i> , 2000, 33, 609-615.	3.7	49
445	The impact of liver disease and medical complications on quality of life and psychological distress before and after liver transplantation. <i>Journal of Hepatology</i> , 2000, 33, 609-615.	3.7	122
446	18 F-fluorodeoxyglucose positron emission tomography study of brain metabolism in cirrhosis: effect of liver transplantation. <i>Transplantation Proceedings</i> , 1999, 31, 418-420.	0.6	19
447	European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. <i>Gastroenterology</i> , 1999, 117, 619-625.	1.3	345
448	EFFECTS OF CYCLOSPORINE IMMUNOSUPPRESSIVE THERAPY ON HUMAN HEMATOPOIESIS IN LIVER TRANSPLANTED PATIENTS. <i>Transplantation</i> , 1999, 67, S635.	1.0	0
449	Bone metabolism in orthotopic liver transplantation: A prospective study. <i>Liver Transplantation</i> , 1998, 4, 311-319.	1.8	49
450	Regional cerebral blood flow changes in patients with cirrhosis assessed with 99m Tc-HM-PAO single-photon emission computed tomography: effect of liver transplantation. <i>Journal of Hepatology</i> , 1998, 29, 78-84.	3.7	40

#	ARTICLE	IF	CITATIONS
451	Protective effect of L-arginine on liver ischemia-reperfusion injury. Transplantation Proceedings, 1997, 29, 393-394.	0.6	13
452	Effect of l-arginine and oligotide on liver ischemia-reperfusion injury. Transplantation Proceedings, 1997, 29, 2992-2993.	0.6	9
453	Evaluation of liver function and morphology following ischemia-reperfusion injury in pigs. Transplantation Proceedings, 1997, 29, 3515-3517.	0.6	2
454	Oxidative Damage in Chronic and Acute Liver Disease.. , 1996, , 24-32.		0
455	Zinc, iron, and peroxidation in liver tissue. Biological Trace Element Research, 1995, 47, 193-199.	3.5	18
456	Liver transplantation and pregnancy. International Journal of Gynecology and Obstetrics, 1995, 50, 199-200.	2.3	10
457	Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. Journal of Hepatology, 1995, 22, 449-456.	3.7	365
458	Human natriuretic factor in cirrhotic patients undergoing orthotopic liver transplantation. Transplant International, 1995, 8, 51-54.	1.6	2
459	Endothelial activation and circulating vascular adhesion molecules in alcoholic liver disease. Hepatology, 1994, 19, 588-594.	7.3	96
460	Aprotinin efficacy on intraoperative bleeding and transfusion requirements in orthotopic liver transplantation. Transfusion, 1994, 34, 507-511.	1.6	48
461	Managing severe alcoholic hepatitis complicated by renal failure. QJM - Monthly Journal of the Association of Physicians, 1993, 86, 649-656.	0.5	39
462	11 beta-Hydroxysteroid dehydrogenase deficiency and glucocorticoid status in patients with alcoholic and non-alcoholic chronic liver disease. Journal of Clinical Endocrinology and Metabolism, 1993, 76, 748-751.	3.6	39
463	Is the intercellular adhesion molecule-1/leukocyte function associated antigen 1 pathway of leukocyte adhesion involved in the tissue damage of alcoholic hepatitis?. Gut, 1992, 33, 268-271.	12.1	52
464	Severity of alcoholic liver disease and markers of thyroid and steroid status. Postgraduate Medical Journal, 1992, 68, 804-810.	1.8	22
465	Detection of circulating intercellular adhesion moleculeâ€“1 in chronic liver diseases. Hepatology, 1992, 16, 810-814.	7.3	94
466	Primary biliary cirrhosis: Symptomatic treatment. Journal of Gastroenterology and Hepatology (Australia), 1991, 6, 570-573.	2.8	17
467	Immune Activation, Exhaustion and Senescence Profiles as Possible Predictors of Cancer in Liver Transplanted Patients. Frontiers in Oncology, 0, 12, .	2.8	1